Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells

Figure 1 Antiproliferative effects of sorafenib, vorinostat, or the drug combination on human hepatoma cell lines. HepG2 (A), Hep3B (B), and PLC/PRF/5 (C) cells were treated with various concentrations of sorafenib, vorinostat, or the drug combination. The results are expressed as the percentage of viable cells in the control group. The results are expressed as mean ± SD from three independent experiments. ^aP < 0.05 and ^bP < 0.01 vs control as evaluated by Student’s t test.